TrialRMD open2024

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.

Laura C Coates et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.